Company profile
Opus Genetics, Inc.
NASDAQ:IRDBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05616793 | phase1_2 | recruiting | 2023-06-15 | 2028-06-15 | Opus Genetics, Inc | Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients |
| NCT07681778 | phase1_2 | not_yet_recruiting | 2026-09-01 | 2032-12-01 | Opus Genetics, Inc | Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) |
| NCT07185256 | phase1_2 | recruiting | 2025-09-25 | 2030-08-01 | Opus Genetics, Inc | Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) |
FDA applications (0)
No records yet.